الفهرس | Only 14 pages are availabe for public view |
Abstract Summary Egypt is known to be among the countries with highest HCV prevalence, with HCV genotype-4 being the predominant genotype in Egypt. The availability of DAAs with excellent efficacy and good tolerability profiles offer a unique opportunity to achieve HCV elimination worldwide. DAA combinations can now cure HCV in more than 95% of patients with HCV infection after 12 weeks of treatment. However, viral clearance with DAAs has led to a global worsening of lipid profile. The purpose of this work was to study the changes in serum lipid profile with INF-free treatment regimens in chronic HCV infection and its association with treatment outcome, and its possible use as a predictor of response to therapy. This prospective observational cohort study was carried out in the Viral Hepatitis Treatment Unit at Tanta University Teaching Hospital. The study included 301 patients with chronic HCV infection, who were treated according to NCCVH treatment protocol. Patients who received antiviral therapy and completed their course of HCV therapy and follow up were included and were divided into two groups according to treatment response. There were 264 patients (88%) who achieved an SVR. Only 4% |